Synthesis, Molecular Modelling and Biological Studies of 3-hydroxy-pyrane-4-one and 3-hydroxy-pyridine-4-one Derivatives as HIV-1 Integrase Inhibitors.

BACKGROUND Despite the progresses in the discovery of antiretroviral compounds for treating HIV-1 infection by targeting HIV integrase (IN), a promising and well-known drug target against HIV-1, there is a growing need to increase the armamentarium against HIV, for avoiding the drug resistance issue. OBJECTIVE To develop novel HIV-1 IN inhibitors, a series of 3-hydroxy-pyrane-4-one (HP) and 3-hydroxy-pyridine-4-one (HPO) derivatives have been rationally designed and synthesized. METHOD To provide a significant characterization of the novel compounds, an in-depth computational analysis was performed using a novel HIV-1 IN/DNA binary 3D-model for investigating the binding mode of the newly conceived molecules in complex with IN. The 3D-model was generated using the proto-type foamy virus (PFV) DNA as a structural template, positioning the viral polydesoxyribonucleic chain into the HIV-1 IN homology model. Moreover, a series of in vitro tests were performed including HIV-1 activity inhibition, HIV-1 IN activity inhibition, HIV-1 IN strand transfer activity inhibition and cellular toxicity. RESULTS Bioassay results indicated that most of HP analogues including HPa, HPb, HPc, HPd, HPe and HPg, showed favorable inhibitory activities against HIV-1-IN in low micromolar range. Particularly halogenated derivatives (HPb and HPd) offered the best biological activities in terms of reduced toxicity and optimum inhibitory activities against HIV-1 IN and HIV-1 in cell culture. CONCLUSION Halogenated derivatives, HPb and HPd, displayed the most promising anti-HIV profile, paving the way to the optimization of the presented scaffolds for developing new effective antiviral agents.

[1]  M. Coletta,et al.  Development of Potent Inhibitors of the Mycobacterium tuberculosis Virulence Factor Zmp1 and Evaluation of Their Effect on Mycobacterial Survival inside Macrophages , 2018, ChemMedChem.

[2]  Simone Brogi,et al.  Structure-based discovery of the first non-covalent inhibitors of Leishmania major tryparedoxin peroxidase by high throughput docking , 2015, Scientific Reports.

[3]  A. Skalka,et al.  Residues critical for retroviral integrative recombination in a region that is highly conserved among retroviral/retrotransposon integrases and bacterial insertion sequence transposases , 1992, Molecular and cellular biology.

[4]  B. Johns,et al.  Advances in two-metal chelation inhibitors of HIV integrase , 2008 .

[5]  E. Novellino,et al.  Optimization of 4-aminoquinoline/clotrimazole-based hybrid antimalarials: further structure-activity relationships, in vivo studies, and preliminary toxicity profiling. , 2012, Journal of medicinal chemistry.

[6]  Roberto D Lins,et al.  Prediction of HIV-1 integrase/viral DNA interactions in the catalytic domain by fast molecular docking. , 2004, Journal of medicinal chemistry.

[7]  A. Engelman,et al.  Retroviral intasome assembly and inhibition of DNA strand transfer , 2010, Nature.

[8]  Y. Pommier,et al.  Probing HIV-1 Integrase Inhibitor Binding Sites with Position-Specific Integrase-DNA Cross-Linking Assays , 2007, Molecular Pharmacology.

[9]  Richard L. Lord,et al.  Ether Cleavage Re-Investigated: Elucidating the Mechanism of BBr3-Facilitated Demethylation of Aryl Methyl Ethers , 2015, European journal of organic chemistry.

[10]  D. van der Helm,et al.  Synthesis, physicochemical properties, and biological evaluation of hydroxypyranones and hydroxypyridinones: novel bidentate ligands for cell-labeling. , 1996, Journal of medicinal chemistry.

[11]  R. Dayam,et al.  HIV-1 Integrase Inhibitors , 2007, Drugs in R&D.

[12]  E. Novellino,et al.  Synthetic spirocyclic endoperoxides: new antimalarial scaffolds , 2015 .

[13]  T. Nilsson,et al.  PREPARATION OF CARBOXYLIC ACIDS FROM ALDEHYDES (INCLUDING HYDROXYLATED BENZALDEHYDES) BY OXIDATION WITH CHLORITE , 1973 .

[14]  Yves Pommier,et al.  Structural and Functional Analyses of the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir (S/GSK1349572) , 2011, Molecular Pharmacology.

[15]  T. Fujiwara,et al.  A platform for designing HIV integrase inhibitors. Part 1: 2-hydroxy-3-heteroaryl acrylic acid derivatives as novel HIV integrase inhibitor and modeling of hydrophilic and hydrophobic pharmacophores. , 2006, Bioorganic & medicinal chemistry.

[16]  P. Charifson,et al.  Are free energy calculations useful in practice? A comparison with rapid scoring functions for the p38 MAP kinase protein system. , 2001, Journal of medicinal chemistry.

[17]  E. Novellino,et al.  From (+)-epigallocatechin gallate to a simplified synthetic analogue as a cytoadherence inhibitor for P. falciparum , 2014 .

[18]  Simone Brogi,et al.  Disease‐Modifying Anti‐Alzheimer's Drugs: Inhibitors of Human Cholinesterases Interfering with β‐Amyloid Aggregation , 2014, CNS neuroscience & therapeutics.

[19]  E. De Clercq,et al.  Assays for the evaluation of HIV-1 integrase inhibitors. , 2001, Methods in molecular biology.

[20]  H. Flood,et al.  The Conversion of Kojic Acid into Comenaldehyde and Comenic Acid. , 1962 .

[21]  R. Hider,et al.  Synthesis of 2-amido-3-hydroxypyridin-4(1H)-ones: novel iron chelators with enhanced pFe3+ values. , 2001, Bioorganic & medicinal chemistry.

[22]  Xiaowu Chen,et al.  Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy. , 2010, Antiviral research.

[23]  Douglas D. Richman,et al.  Probing chelation motifs in HIV integrase inhibitors , 2012, Proceedings of the National Academy of Sciences.

[24]  P. Quinn,et al.  Design, synthesis, physicochemical properties, and evaluation of novel iron chelators with fluorescent sensors. , 2004, Journal of medicinal chemistry.

[25]  Kazunari Hattori,et al.  Dolutegravir Interactions with HIV-1 Integrase-DNA: Structural Rationale for Drug Resistance and Dissociation Kinetics , 2013, PloS one.

[26]  Simone Brogi,et al.  Rational design of the first difluorostatone-based PfSUB1 inhibitors. , 2014, Bioorganic & medicinal chemistry letters.

[27]  Y. Pommier,et al.  Integrase inhibitors to treat HIV/Aids , 2005, Nature Reviews Drug Discovery.

[28]  Amy S. Espeseth,et al.  HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Y. Pommier,et al.  Resistance to Integrase Inhibitors , 2010, Viruses.

[30]  J. Briggs,et al.  Investigations on human immunodeficiency virus type 1 integrase/DNA binding interactions via molecular dynamics and electrostatics calculations. , 2000, Pharmacology & therapeutics.

[31]  Y. Pommier,et al.  Structural Determinants for HIV-1 Integrase Inhibition by β-Diketo Acids* , 2002, The Journal of Biological Chemistry.

[32]  Garrett M Morris,et al.  Assessing the role of polarization in docking. , 2008, The journal of physical chemistry. A.

[33]  Maxwell D. Cummings,et al.  Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance , 2010, Proceedings of the National Academy of Sciences.

[34]  D. Davies,et al.  Structure and function of HIV-1 integrase. , 2004, Current topics in medicinal chemistry.

[35]  E. De Clercq,et al.  In Search of Authentic Inhibitors of HIV-1 Integration , 2002, Antiviral chemistry & chemotherapy.

[36]  Simone Brogi,et al.  In silico study of subtilisin-like protease 1 (SUB1) from different Plasmodium species in complex with peptidyl-difluorostatones and characterization of potent pan-SUB1 inhibitors , 2016, Journal of molecular graphics & modelling.

[37]  P. Roversi,et al.  Functional and structural characterization of the integrase from the prototype foamy virus , 2008, Nucleic acids research.

[38]  Matthew P. Repasky,et al.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.

[39]  J. Preston,et al.  A RAPID SYNTHESIS OF OLIGOPEPTIDE DERIVATIVES WITHOUT ISOLATION OF INTERMEDIATES. , 1965, Journal of the American Chemical Society.

[40]  Amy S. Espeseth,et al.  Diketo acid inhibitor mechanism and HIV-1 integrase: Implications for metal binding in the active site of phosphotransferase enzymes , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[41]  M. Matsuoka,et al.  Broad Antiretroviral Activity and Resistance Profile of the Novel Human Immunodeficiency Virus Integrase Inhibitor Elvitegravir (JTK-303/GS-9137) , 2007, Journal of Virology.

[42]  A. Engelman,et al.  Identification of conserved amino acid residues critical for human immunodeficiency virus type 1 integrase function in vitro , 1992, Journal of virology.

[43]  Ian W. Davis,et al.  Structure validation by Cα geometry: ϕ,ψ and Cβ deviation , 2003, Proteins.

[44]  P. Kollman,et al.  Binding of a diverse set of ligands to avidin and streptavidin: an accurate quantitative prediction of their relative affinities by a combination of molecular mechanics and continuum solvent models. , 2000, Journal of medicinal chemistry.

[45]  E. Zubin,et al.  Probing of HIV-1 Integrase/DNA Interactions Using Novel Analogs of Viral DNA* , 2006, Journal of Biological Chemistry.

[46]  Simone Brogi,et al.  Synthesis and structure-activity relationship studies in serotonin 5-HT(1A) receptor agonists based on fused pyrrolidone scaffolds. , 2013, European journal of medicinal chemistry.

[47]  Dirk Strumberg,et al.  Metal-dependent inhibition of HIV-1 integrase. , 2002, Journal of medicinal chemistry.

[48]  D. Hazuda,et al.  Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. , 2008, Journal of medicinal chemistry.

[49]  I. Weber,et al.  Defining the DNA substrate binding sites on HIV-1 integrase. , 2009, Journal of molecular biology.

[50]  J Desmyter,et al.  Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. , 1988, Journal of virological methods.

[51]  Niu Huang,et al.  Physics-Based Scoring of Protein-Ligand Complexes: Enrichment of Known Inhibitors in Large-Scale Virtual Screening , 2006, J. Chem. Inf. Model..

[52]  Victor Guallar,et al.  Importance of accurate charges in molecular docking: Quantum mechanical/molecular mechanical (QM/MM) approach , 2005, J. Comput. Chem..

[53]  F. Bailly,et al.  4-Substituted 2-Hydroxyisoquinoline-1,3(2H,4H)-diones as a Novel Class of HIV-1 Integrase Inhibitors. , 2013, ACS medicinal chemistry letters.

[54]  C. Katlama,et al.  Dolutegravir for the treatment of HIV , 2012, Expert opinion on investigational drugs.

[55]  A. Engelman,et al.  Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases. , 1994, Science.

[56]  M. Rowley.  The discovery of raltegravir, an integrase inhibitor for the treatment of HIV infection. , 2008, Progress in medicinal chemistry.

[57]  Simone Brogi,et al.  Structural characterization of Giardia duodenalis thioredoxin reductase (gTrxR) and computational analysis of its interaction with NBDHEX. , 2017, European journal of medicinal chemistry.

[58]  A. Engelman,et al.  Structure-based modeling of the functional HIV-1 intasome and its inhibition , 2010, Proceedings of the National Academy of Sciences.

[59]  F Bushman,et al.  Rapid microtiter assays for poxvirus topoisomerase, mammalian type IB topoisomerase and HIV-1 integrase: application to inhibitor isolation. , 2000, Nucleic acids research.

[60]  Simone Brogi,et al.  Discovery and Cardioprotective Effects of the First Non-Peptide Agonists of the G Protein-Coupled Prokineticin Receptor-1 , 2015, PloS one.

[61]  Jonathan W. Essex,et al.  A review of protein-small molecule docking methods , 2002, J. Comput. Aided Mol. Des..

[62]  Sérgio M. Marques,et al.  Hydroxypyridinones as “privileged” chelating structures for the design of medicinal drugs , 2012 .

[63]  T. Seki,et al.  Carbamoyl pyridone HIV-1 integrase inhibitors. 1. Molecular design and establishment of an advanced two-metal binding pharmacophore. , 2012, Journal of medicinal chemistry.

[64]  A. Fassihi,et al.  Docking studies of some 5-hydroxypyridine-4-one derivatives: evaluation of integrase and ribonuclease H domain of reverse transcriptase as possible targets for anti-HIV-1 activity , 2015, Medicinal Chemistry Research.

[65]  Development of integrase inhibitors for treatment of AIDS: an overview. , 2007, European journal of medicinal chemistry.

[66]  J Andrew McCammon,et al.  Potent, selective pyrone-based inhibitors of stromelysin-1. , 2005, Journal of the American Chemical Society.

[67]  A. Fassihi,et al.  Design, synthesis and anti-HIV-1 evaluation of a series of 5-hydroxypyridine-4-one derivatives as possible integrase inhibitors , 2015, Medicinal Chemistry Research.

[68]  Akihiko Sato,et al.  A platform for designing HIV integrase inhibitors. Part 2: a two-metal binding model as a potential mechanism of HIV integrase inhibitors. , 2006, Bioorganic & medicinal chemistry.

[69]  S. Ikeda,et al.  Quinolone carboxylic acids as a novel monoketo acid class of human immunodeficiency virus type 1 integrase inhibitors. , 2009, Journal of medicinal chemistry.

[70]  J. Kjems,et al.  Mapping DNA-binding sites of HIV-1 integrase by protein footprinting. , 2001, European journal of biochemistry.

[71]  D. Eisenberg,et al.  Assessment of protein models with three-dimensional profiles , 1992, Nature.

[72]  Y. Pommier,et al.  Scaffold rearrangement of dihydroxypyrimidine inhibitors of HIV integrase: Docking model revisited. , 2010, Bioorganic & medicinal chemistry letters.